INTRODUCTION
The discovery of the new quinolones has broadened rather unexpectedly the therapeutic armamentarium against infections with mycobacteria. It has indeed been several years since new compounds with such an antimycobacterial potential were developed.
The lead compound of these DNA gyrase-inhibiting antibacterial agents (28, 63) , norfloxacin, is not very active; but the N-cyclopropylanalog ciprofloxacin and the tricyclic ofloxacin deserve full attention. Moreover, these compounds appear to penetrate readily into mammalian cells. This property is important for the treatment of intracellular pathogens, such as Mycobacterium tuberculosis (14, 15) .
This review gives a survey of most of the studies, in vitro as well as in vivo, published on the antimycobacterial activities of the new quinolones. IN 
VITRO ACTIVITY
The main results of in vitro tests of four important quinolones are summarized in Tables 1 to 3 . Although published data on the in vitro antimycobacterial activities of these quinolones are based on different susceptibility testing methods, results can easily be summarized. Some discrepancies may be the result of differences in method. It is, however, shown that MICs vary little, regardless of whether agar or broth dilution was used (48 (2, 9, 13, 16, 22, 25, 37, 52, 66) . However, since different comparison agents were used in these studies it is difficult to be certain about the activities of these compounds in relation to the parent compounds.
The quinolones appear to be bactericidal against M. tuberculosis (3). MBCs were only double the MICs (22) . Sub-MICs (0.2 to 0.5 ,ug/ml) decreased the speed of growth. This was also seen with other tuberculostatic agents, except isoniazid (50) . Ciprofloxacin was proven to be bactericidal at levels achievable in serum against five of seven strains of M. avium isolated from patients with acquired immunodeficiency syndrome. For these strains, MICs and MBCs were <2 ,ug/ml. The MBC/MIC ratio was between 2 and 1. The ratio for the less-susceptible strains was 4 (65) .
These in vitro studies have also shown that the activity of the new quinolones is independent of resistance to other antimycobacterial agents.
There was no synergism nor antagonism between the older drugs and the quinolones; the effects were additive (22, 35, 40, 50) .
Resistance to quinolones shows an obligatory two-step pattern. There are two phenotypes for ofloxacin: one is resistance to 5 ,ug/ml and one is resistance to 100 pug/ml (50) .
Finally, quinolones also are interesting compounds for taxonomic studies: ofloxacin susceptibility differentiated between M. nonchromogenicum, M. terrae, and M. triviale (49) . M. fortuitum and M. chelonae can be distinguished from other mycobacteria through their resistance to ofloxacin, enoxacin, and ciprofloxacin (4, 46) . Enoxacin was used to differentiate between M. gordonae, M. scrofulaceum, and M. szulgai (52) .
PHARMACOKINETIC PROPERTIES The pharmacokinetic properties of the quinolones play an important role in their therapeutic usefulness. Ofloxacin and pefloxacin, both N-methylpiperazine derivatives, are better (about 90%) absorbed after oral administration than is ciprofloxacin (about 60%). Maximum levels in serum are also higher for the N-methyl compounds. An oral dose of 500 mg gives a maximum level of about 10 ,ug/ml for ofloxacin and about 2.5 ,ug/ml for ciprofloxacin. The same accounts for the elimination half-lives, about 4 and 7 h, respectively. Both compounds have relatively high distribution volumes: for ofloxacin, it is about 100 to 120 liters, and it is even higher for ciprofloxacin (33, 36, 61, 62) .
Distribution in tissues and body fluids has been studied in humans. Some general data are found in references 6 and 33. The compounds mentioned above accumulated in lung tissue. Ofloxacin was found to penetrate equally in healthy and atelectatic pulmonary tissues. During a twice-daily 200-mg regimen, levels of 6.7 + 1.0 (mean ± standard deviation) ,ug/ g were found. The tissue-serum ratio was about 2.8 (5, 8) . The same applies to ciprofloxacin (8, 61) . Ofloxacin levels in sputum of about 3.0 ,ug/ml were found (sputum-serum ratio, 0.75) with regimens of 400 mg twice a day. The AUC ratio was about 1. These ratios were lower for ciprofloxacin: 0.4 and 0.5, respectively, during a regimen of 500 mg twice a day (34, 36, 45, 61) .
The above-mentioned values are all above the MIC for M. tuberculosis. Therapeutic levels were also found in blister fluid (31, 61) , infected bone (18, 61), soft tissue (32), skin (11, 32) , muscle (11, 18, 61) , liver (11), gynecological tissues (23, 60) , prostate (6, 61) , and pleural fluid (61) . IN 
VIVO ACTIVITY
M. tuberculosis. In experimental mouse tuberculosis treated with ofloxacin (42 ,ug/g), there was a significant decrease in the number of organisms in the liver (51) . Ciprofloxacin (160 ,ug/g) for 90 days also showed good activity in this model. The combination ciprofloxacin-isoniazid appeared to be very effective (44) .
Combined chemotherapy with ofloxacin, rifampin, and isoniazid was given to 17 previously untreated patients with pulmonary tuberculosis. The average time for conversion of sputum cultures from positive to negative was 1.8 months. These results were comparable to those obtained with other drug combinations with first-choice antitubercular drugs. The ofloxacin-containing treatment did not show any particular side effects (58) .
Ofloxacin (300 mg/day for 1 year) was also used with 16 patients with chronic tuberculosis who had been unsuccessfully treated with different antitubercular regimens. A decrease in the number of organisms in sputum was seen in all patients. Sputum conversion was achieved in at least five patients, and in three patients sputum cultures became negative during further treatment (56, 57) . Ofloxacin was the only agent in the multidrug regimens used to which M. tuberculosis was not initially resistant. Not unexpectedly, ofloxacin resistance developed in this setting. Pefloxacin, although less active in vitro, was successfully ,ug/g when administered at least three times a week (Pattyn, used in combination therapy in a case of tuberculosis which Letter). The results with ofloxacin were confirmed in anhad not responded to usual treatments (20) .
other study (43 31:671-672, 1987) . Pefloxacin showed activity at 300 pharmacokinetic properties of ciprofloxacin in mice (24) . (64) . Ofloxacin was successfully used for a patient with a M. fortuitum lung infection. This patient had been treated without success with a series of antimycobacterial agents in combination therapies (27, 53) .
COMMENTS
Although for some mycobacteria the number of strains tested was rather small and further in vivo studies are necessary, it is clear that the new quinolones are candidates to join the family of antimycobacterial drugs. Ofloxacin and ciprofloxacin are the most active drugs. They also show suitable pharmacokinetic properties. Ofloxacin seems to possess the best properties: levels in tissues and elimination half-lives are higher. Moreover, as mentioned above, these drugs penetrate well into mammalian cells (14, 15) . These drugs could be useful in the treatment of tuberculosis and other mycobacterioses with slowly and rapidly growing mycobacteria, including M. leprae.
It should, however, be borne in mind that emergence of resistance is common with the quinolone agents. This resistance is probably the result of selection of pre-existing mutants, since there is no evidence for plasmid-mediated resistance (59) .
Drug interactions for ofloxacin have not been described.
With ciprofloxacin, interactions with the pharmacokinetics of theophylline are possible. Levels in serum increase, and dosage adjustment of theophylline could be necessary (19, 38) . Antacids may delay the absorption and decrease the amount absorbed (42) .
Finally, it should be mentioned that the side-effect profile of the new quinolones is rather favorable. The main complaints are gastrointestinal disturbances, such as nausea, anorexia, and diarrhea (2 to 3% of patients). About 0.5 to 1% of patients show central nervous system side effects, such as insomnia, headache, and dizziness. Some patients (0.5%) complain of skin rashes, and phototoxicity is possible (1, 28) . There is insufficient experience with prolonged quinolone therapy to determine the extent of long-term side effects.
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